Related references
Note: Only part of the references are listed.Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
P. Fenaux et al.
ANNALS OF ONCOLOGY (2021)
S100A6 is a critical regulator of hematopoietic stem cells
Tan Hooi Min Grahn et al.
LEUKEMIA (2020)
Prognostic Markers of Myelodysplastic Syndromes
Yuliya Andreevna Veryaskina et al.
MEDICINA-LITHUANIA (2020)
S100A6 promotes proliferation of intrahepatic cholangiocarcinoma cells via the activation of the p38/MAPK pathway
Susu Zheng et al.
FUTURE ONCOLOGY (2017)
The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia
Adam S. Sperling et al.
NATURE REVIEWS CANCER (2017)
S100A6-focus on recent developments
Wieslawa Lesniak et al.
BIOLOGICAL CHEMISTRY (2017)
S100A6 protein: functional roles
Rosario Donato et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2017)
Overexpression of BMI1 confers clonal cells resistance to apoptosis and contributes to adverse prognosis in myelodysplastic syndrome
Feng Xu et al.
CANCER LETTERS (2012)
Apoptosis in relation to CD34 antigen expression in normal and myelodysplastic bone marrow
A Pecci et al.
ACTA HAEMATOLOGICA (2003)
Share Paper
